PriceTargets.com logo

IQVIA - IQV Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $241.44
  • Forecasted Upside: 7.41%
  • Number of Analysts: 23
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 15 Buy Ratings
  • 2 Strong Buy Ratings
$224.78 As of 12/4/2025 04:59 PM ET
▼ -2.457 (-1.08%)

This chart shows the closing price for IQV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IQVIA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IQV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IQV

Analyst Price Target is $241.44
▲ +7.41% Upside Potential
This price target is based on 23 analysts offering 12 month price targets for IQVIA in the last 3 months. The average price target is $241.44, with a high forecast of $270.00 and a low forecast of $200.00. The average price target represents a 7.41% upside from the last price of $224.78.

This chart shows the closing price for IQV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 23 investment analysts is to moderate buy stock in IQVIA. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 16 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 17 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 15 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 15 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 15 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$250.00 ➝ $265.00
11/13/2025BMO Capital MarketsInitiated CoverageOutperform$260.00
11/3/2025CowenDowngradeBuy ➝ Hold
11/3/2025TD CowenDowngradeBuy ➝ Hold$206.00 ➝ $215.00
10/29/2025Stifel NicolausBoost TargetBuy ➝ Buy$234.00 ➝ $254.00
10/29/2025UBS GroupBoost TargetBuy ➝ Buy$225.00 ➝ $250.00
10/29/2025CitigroupBoost TargetNeutral ➝ Neutral$200.00 ➝ $230.00
10/29/2025Robert W. BairdSet TargetNeutral ➝ Outperform$224.00 ➝ $258.00
10/29/2025Baird R WUpgradeHold ➝ Strong-Buy
10/29/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$177.00 ➝ $255.00
10/29/2025Truist FinancialReiterated RatingBuy ➝ Buy$235.00 ➝ $265.00
10/9/2025HSBCUpgradeHold ➝ Buy$195.00 ➝ $235.00
10/9/2025Hsbc Global ResUpgradeHold ➝ Strong-Buy
10/8/2025Evercore ISIBoost TargetOutperform ➝ Outperform$220.00 ➝ $240.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/2/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$185.00 ➝ $200.00
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/9/2025Jefferies Financial GroupUpgradeHold ➝ Buy$195.00 ➝ $225.00
9/3/2025Redburn PartnersSet Target$214.00
7/25/2025MizuhoBoost TargetOutperform ➝ Outperform$190.00 ➝ $225.00
7/23/2025CowenReiterated RatingBuy ➝ Buy
7/23/2025UBS GroupBoost TargetBuy ➝ Buy$185.00 ➝ $225.00
7/23/2025William BlairReiterated RatingOutperform
7/23/2025Truist FinancialBoost TargetBuy ➝ Buy$209.00 ➝ $235.00
7/23/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$165.00 ➝ $185.00
7/23/2025Robert W. BairdBoost TargetNeutral ➝ Neutral$159.00 ➝ $196.00
7/9/2025Evercore ISIBoost TargetOutperform ➝ Outperform$170.00 ➝ $180.00
5/23/2025Redburn PartnersSet Target$188.00
5/22/2025CitigroupReiterated RatingNeutral ➝ Neutral
5/19/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$232.00 ➝ $177.00
5/15/2025MizuhoLower TargetOutperform ➝ Outperform$210.00 ➝ $190.00
5/7/2025Robert W. BairdLower TargetNeutral ➝ Neutral$195.00 ➝ $161.00
5/7/2025UBS GroupLower TargetBuy ➝ Buy$255.00 ➝ $185.00
5/7/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$170.00 ➝ $165.00
4/25/2025Hsbc Global ResDowngradeStrong-Buy ➝ Hold
4/25/2025HSBCDowngradeBuy ➝ Hold$260.00 ➝ $160.00
4/10/2025BarclaysReiterated RatingOverweight ➝ Equal Weight$235.00 ➝ $170.00
4/10/2025Truist FinancialLower TargetBuy ➝ Buy$263.00 ➝ $216.00
4/9/2025MizuhoLower TargetOutperform ➝ Outperform$242.00 ➝ $210.00
3/4/2025CitigroupLower TargetNeutral ➝ Neutral$225.00 ➝ $210.00
2/18/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$240.00 ➝ $232.00
2/11/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$245.00 ➝ $250.00
2/10/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00
2/10/2025Truist FinancialReiterated RatingBuy ➝ Buy$261.00 ➝ $263.00
2/7/2025UBS GroupLower TargetBuy ➝ Buy$260.00 ➝ $255.00
2/7/2025Stifel NicolausLower TargetBuy ➝ Buy$273.00 ➝ $261.00
2/3/2025BarclaysLower TargetOverweight ➝ Overweight$255.00 ➝ $235.00
2/3/2025BTIG ResearchDowngradeBuy ➝ Neutral
1/21/2025Robert W. BairdLower TargetNeutral ➝ Neutral$212.00 ➝ $210.00
12/20/2024StephensInitiated CoverageOverweight$250.00
12/13/2024Bank of AmericaLower TargetBuy ➝ Buy$255.00 ➝ $235.00
12/12/2024Truist FinancialLower TargetBuy ➝ Buy$265.00 ➝ $261.00
12/11/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00
12/11/2024Robert W. BairdLower TargetNeutral ➝ Neutral$213.00 ➝ $212.00
12/11/2024William BlairReiterated RatingOutperform
12/4/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00
11/19/2024Leerink PartnersReiterated RatingOutperform ➝ Outperform$260.00 ➝ $248.00
11/5/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$279.00 ➝ $240.00
11/4/2024Truist FinancialLower TargetBuy ➝ Buy$286.00 ➝ $265.00
11/4/2024Morgan StanleyLower TargetOverweight ➝ Overweight$280.00 ➝ $265.00
11/1/2024BTIG ResearchLower TargetBuy ➝ Buy$290.00 ➝ $260.00
11/1/2024BarclaysLower TargetOverweight ➝ Overweight$260.00 ➝ $255.00
11/1/2024Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$270.00 ➝ $265.00
11/1/2024TD CowenLower TargetBuy ➝ Buy$270.00 ➝ $255.00
11/1/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00
11/1/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$280.00 ➝ $250.00
11/1/2024Robert W. BairdLower TargetNeutral ➝ Neutral$256.00 ➝ $223.00
10/23/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$288.00 ➝ $279.00
10/15/2024BarclaysLower TargetOverweight ➝ Overweight$275.00 ➝ $260.00
10/14/2024Truist FinancialLower TargetBuy ➝ Buy$300.00 ➝ $286.00
10/14/2024Redburn AtlanticInitiated CoverageBuy$276.00
10/8/2024Evercore ISILower TargetOutperform ➝ Outperform$270.00 ➝ $265.00
9/20/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$251.00 ➝ $256.00
9/4/2024Royal Bank Of CanadaInitiated CoverageOutperform$275.00
8/5/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$260.00 ➝ $288.00
7/31/2024ArgusUpgradeStrong-Buy
7/24/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$266.00 ➝ $242.00
7/23/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$270.00 ➝ $280.00
7/23/2024UBS GroupBoost TargetBuy ➝ Buy$295.00 ➝ $300.00
7/23/2024Evercore ISIBoost TargetOutperform ➝ Outperform$230.00 ➝ $270.00
7/23/2024Truist FinancialBoost TargetBuy ➝ Buy$292.00 ➝ $300.00
7/23/2024BarclaysBoost TargetOverweight ➝ Overweight$255.00 ➝ $275.00
7/23/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$235.00 ➝ $251.00
7/10/2024Robert W. BairdLower TargetNeutral ➝ Neutral$241.00 ➝ $235.00
7/9/2024Evercore ISILower TargetOutperform ➝ Outperform$250.00 ➝ $230.00
6/28/2024BarclaysLower TargetOverweight ➝ Overweight$275.00 ➝ $255.00
6/6/2024The Goldman Sachs GroupInitiated CoverageBuy$270.00
5/3/2024Evercore ISILower TargetOutperform ➝ Outperform$275.00 ➝ $250.00
5/3/2024Truist FinancialLower TargetBuy ➝ Buy$297.00 ➝ $292.00
5/3/2024Robert W. BairdLower TargetNeutral ➝ Neutral$254.00 ➝ $245.00
2/27/2024Truist FinancialBoost TargetBuy ➝ Buy$286.00 ➝ $297.00
2/26/2024Leerink PartnrsReiterated RatingOutperform
2/26/2024Leerink PartnersInitiated CoverageOutperform$290.00
2/15/2024Evercore ISIBoost TargetOutperform ➝ Market Outperform$255.00 ➝ $265.00
2/15/2024UBS GroupBoost TargetBuy ➝ Buy$240.00 ➝ $300.00
2/15/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$226.00 ➝ $251.00
2/15/2024BarclaysBoost TargetOverweight ➝ Overweight$260.00 ➝ $265.00
2/15/2024GuggenheimDowngradeBuy ➝ Neutral
2/13/2024BTIG ResearchInitiated CoverageBuy$285.00
1/25/2024BarclaysBoost TargetOverweight ➝ Overweight$215.00 ➝ $260.00
1/18/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$221.00 ➝ $226.00
1/4/2024Truist FinancialBoost TargetBuy ➝ Buy$240.00 ➝ $286.00
12/11/2023CitigroupBoost TargetNeutral ➝ Neutral$190.00 ➝ $225.00
11/21/2023Truist FinancialReiterated RatingBuy ➝ Buy$240.00
11/13/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$262.00 ➝ $239.00
11/3/2023Morgan StanleyLower TargetOverweight ➝ Overweight$240.00 ➝ $225.00
11/3/2023Truist FinancialLower TargetBuy ➝ Buy$260.00 ➝ $240.00
11/3/2023GuggenheimLower TargetBuy ➝ Buy$253.00 ➝ $220.00
11/2/2023BarclaysLower TargetOverweight ➝ Overweight$245.00 ➝ $215.00
11/2/2023Robert W. BairdDowngradeOutperform ➝ Neutral$248.00 ➝ $202.00
10/17/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$239.00 ➝ $248.00
10/11/2023Evercore ISILower Target$260.00 ➝ $240.00
10/10/2023MizuhoLower TargetBuy ➝ Buy$250.00 ➝ $229.00
10/3/2023Truist FinancialReiterated RatingBuy ➝ Buy$260.00
9/29/2023BarclaysLower TargetOverweight ➝ Overweight$250.00 ➝ $245.00
9/6/2023HSBCInitiated CoverageBuy$260.00
8/2/2023CitigroupBoost TargetNeutral ➝ Neutral$200.00 ➝ $225.00
8/2/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$220.00 ➝ $240.00
8/2/2023Stifel NicolausBoost TargetBuy ➝ Buy$255.00 ➝ $281.00
7/18/2023Truist FinancialBoost TargetBuy$244.00 ➝ $260.00
6/27/2023BarclaysBoost Target$230.00 ➝ $250.00
5/1/2023Truist FinancialLower Target$265.00 ➝ $244.00
5/1/2023Wells Fargo & CompanyLower Target$235.00 ➝ $220.00
4/28/2023Stifel NicolausLower Target$269.00 ➝ $255.00
4/28/2023GuggenheimLower Target$266.00 ➝ $258.00
4/28/2023Robert W. BairdLower Target$240.00 ➝ $235.00
4/4/2023BarclaysLower TargetOverweight$260.00 ➝ $230.00
3/17/2023Truist FinancialInitiated CoverageBuy$265.00
2/27/2023JPMorgan Chase & Co.Boost TargetOverweight$257.00 ➝ $263.00
2/13/2023Credit Suisse GroupReiterated RatingOutperform$265.00
2/13/2023Morgan StanleyBoost TargetOverweight$240.00 ➝ $260.00
1/27/2023Leerink PartnersReiterated RatingOutperform
1/13/2023Robert W. BairdLower TargetOutperform$266.00 ➝ $260.00
12/6/2022CowenInitiated CoverageOutperform$251.00
12/6/2022CowenInitiated CoverageOutperform
11/17/2022CitigroupDowngradeBuy ➝ Neutral$275.00 ➝ $245.00
11/10/2022MizuhoLower TargetBuy$270.00 ➝ $250.00
10/27/2022GuggenheimBoost Target$249.00
10/27/2022Robert W. BairdBoost Target$266.00
10/27/2022Morgan StanleyLower TargetOverweight$260.00 ➝ $240.00
10/27/2022Credit Suisse GroupLower TargetOutperform$300.00 ➝ $265.00
10/27/2022CitigroupLower TargetBuy$290.00 ➝ $275.00
10/27/2022BarclaysBoost TargetOverweight$215.00 ➝ $235.00
10/18/2022Deutsche Bank AktiengesellschaftLower Target$290.00 ➝ $270.00
10/10/2022GuggenheimLower TargetBuy$246.00 ➝ $234.00
10/6/2022BarclaysLower TargetOverweight$235.00 ➝ $215.00
9/12/2022BarclaysLower TargetOverweight$255.00 ➝ $235.00
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$300.00
8/18/2022ArgusBoost Target$260.00 ➝ $275.00
7/22/2022GuggenheimBoost Target$246.00
7/22/2022Morgan StanleyBoost TargetOverweight$255.00 ➝ $260.00
7/22/2022Evercore ISIBoost Target$265.00 ➝ $275.00
7/22/2022Robert W. BairdBoost Target$260.00 ➝ $265.00
7/15/2022Leerink PartnersInitiated CoverageOutperform$256.00
7/13/2022BarclaysLower TargetOverweight$240.00 ➝ $236.00
5/23/2022GuggenheimInitiated CoverageBuy$244.00
4/28/2022Piper SandlerUpgradeNeutral ➝ Overweight$231.00 ➝ $255.00
4/28/2022BarclaysLower Target$275.00 ➝ $240.00
4/25/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$290.00 ➝ $235.00
4/12/2022Deutsche Bank AktiengesellschaftBoost TargetBuy$250.00 ➝ $290.00
3/23/2022Deutsche Bank AktiengesellschaftLower TargetBuy$255.00 ➝ $250.00
3/7/2022MizuhoLower TargetBuy$300.00 ➝ $270.00
2/17/2022Piper SandlerLower TargetNeutral$261.00 ➝ $231.00
2/17/2022Deutsche Bank AktiengesellschaftLower Target$282.00 ➝ $255.00
2/16/2022William BlairReiterated RatingOutperform
2/16/2022Morgan StanleyLower TargetOverweight$290.00 ➝ $280.00
2/16/2022UBS GroupLower Target$310.00 ➝ $290.00
12/20/2021MizuhoBoost TargetBuy$290.00 ➝ $300.00
11/18/2021Piper SandlerBoost TargetNeutral$250.00 ➝ $261.00
11/18/2021MizuhoBoost TargetBuy$282.00 ➝ $290.00
11/17/2021Jefferies Financial GroupBoost TargetBuy$300.00 ➝ $309.00
11/17/2021CitigroupBoost TargetBuy$300.00 ➝ $320.00
11/17/2021KeyCorpBoost TargetOverweight$270.00 ➝ $290.00
11/17/2021UBS GroupBoost TargetPositive ➝ Buy$298.00 ➝ $310.00
11/12/2021Evercore ISIReiterated RatingOutperform
10/28/2021MizuhoBoost TargetBuy$270.00 ➝ $282.00
10/27/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$250.00 ➝ $282.00
10/25/2021BarclaysBoost TargetOverweight$285.00 ➝ $287.00
10/22/2021Stifel NicolausBoost TargetBuy$300.00 ➝ $304.00
10/22/2021Morgan StanleyBoost TargetOverweight$280.00 ➝ $290.00
10/22/2021CitigroupBoost TargetBuy$280.00 ➝ $300.00
10/15/2021KeyCorpBoost TargetOverweight$260.00 ➝ $270.00
9/10/2021ArgusBoost TargetBuy$260.00 ➝ $290.00
7/28/2021Morgan StanleyBoost TargetOverweight$260.00 ➝ $280.00
7/28/2021MizuhoBoost TargetBuy$250.00 ➝ $270.00
7/28/2021Piper SandlerBoost TargetNeutral$204.00 ➝ $235.00
7/28/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$244.00 ➝ $250.00
7/28/2021CitigroupBoost TargetBuy$265.00 ➝ $280.00
7/28/2021Robert W. BairdBoost TargetOutperform$273.00 ➝ $285.00
7/20/2021Credit Suisse GroupBoost TargetOutperform$242.00 ➝ $265.00
7/13/2021BarclaysBoost TargetOverweight$260.00 ➝ $285.00
5/14/2021KeyCorpBoost TargetOverweight$255.00 ➝ $260.00
5/12/2021ArgusBoost TargetBuy$220.00 ➝ $260.00
4/26/2021Truist FinancialBoost TargetBuy$235.00 ➝ $260.00
4/26/2021Morgan StanleyBoost TargetOverweight$220.00 ➝ $260.00
4/26/2021BarclaysBoost TargetOverweight$235.00 ➝ $260.00
4/23/2021CitigroupBoost Target$225.00 ➝ $265.00
4/23/2021Jefferies Financial GroupBoost TargetBuy$259.00 ➝ $273.00
4/23/2021Robert W. BairdBoost TargetOutperform$238.00 ➝ $250.00
4/23/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$200.00 ➝ $244.00
4/23/2021MizuhoBoost TargetBuy$218.00 ➝ $250.00
4/16/2021StephensUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.00
4/9/2021MizuhoBoost TargetBuy$210.00 ➝ $218.00
3/15/2021KeyCorpUpgradeSector Weight ➝ Overweight$218.00
3/8/2021BarclaysInitiated CoverageOverweight$220.00
3/2/2021BarclaysInitiated CoverageOverweight$220.00
2/11/2021Truist FinancialBoost Target$197.00 ➝ $235.00
2/11/2021Wells Fargo & CompanyBoost TargetOverweight$205.00 ➝ $230.00
2/11/2021Robert W. BairdBoost TargetOutperform$208.00 ➝ $221.00
2/11/2021Morgan StanleyBoost TargetOverweight$205.00 ➝ $220.00
2/11/2021MizuhoBoost TargetBuy$200.00 ➝ $210.00
2/11/2021Piper SandlerBoost TargetNeutral$179.00 ➝ $204.00
12/18/2020MizuhoBoost TargetBuy$190.00 ➝ $200.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.30 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 49 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 79 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 91 very positive mentions
  • 37 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 108 very positive mentions
  • 31 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 108 very positive mentions
  • 31 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

IQVIA logo
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $224.78
Low: $214.01
High: $227.53

50 Day Range

MA: $213.56
Low: $179.51
High: $231.89

52 Week Range

Now: $224.78
Low: $134.65
High: $234.29

Volume

3,298,872 shs

Average Volume

1,290,098 shs

Market Capitalization

$38.28 billion

P/E Ratio

30.83

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of IQVIA?

The following Wall Street analysts have issued reports on IQVIA in the last twelve months: Baird R W, Bank of America Corporation, Barclays PLC, BMO Capital Markets, BTIG Research, Citigroup Inc., Cowen Inc, Evercore ISI, Hsbc Global Res, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Redburn Partners, Robert W. Baird, Royal Bank Of Canada, Stephens, Stifel Nicolaus, TD Cowen, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and William Blair.
View the latest analyst ratings for IQV.

What is the current price target for IQVIA?

0 Wall Street analysts have set twelve-month price targets for IQVIA in the last year. Their average twelve-month price target is $241.44, suggesting a possible upside of 7.4%. Royal Bank Of Canada has the highest price target set, predicting IQV will reach $270.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $200.00 for IQVIA in the next year.
View the latest price targets for IQV.

What is the current consensus analyst rating for IQVIA?

IQVIA currently has 6 hold ratings, 15 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IQV.

What other companies compete with IQVIA?

Other companies that are similar to IQVIA include Icon, Medpace, Bio-Techne, Agilent Technologies and Charles River Laboratories International. Learn More about companies similar to IQVIA.

How do I contact IQVIA's investor relations team?

IQVIA's physical mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company's listed phone number is (919) 998-2000 and its investor relations email address is [email protected]. The official website for IQVIA is www.iqvia.com. Learn More about contacing IQVIA investor relations.